Life Sciences

  • August 25, 2026

    Rising Star: Williams & Connolly's Kathryn Kayali

    Kathryn Kayali of Williams & Connolly LLP has helped secure major wins in high-profile pharmaceutical patent litigation over COVID-19 vaccines and played a role in landing the first injunctions under the Biologics Price Competition and Innovation Act, earning her a spot among life sciences lawyers under age 40 honored by Law360 as Rising Stars.

  • August 25, 2026

    Judge Allows Hospital Groups To Fight AbbVie 340B Suit

    A D.C. federal judge will allow hospitals and health center groups to intervene on the side of the government as it fights AbbVie's challenge to the definition of "patient" in the 340B drug discount program, ruling that the providers would suffer concrete financial harm if the pharmaceutical company's interpretation prevails.

  • August 24, 2026

    'So What?': Albertsons Judge Skeptical Of Wash. Opioid Suit

    A Washington state judge considering Albertsons' mid-trial motion to dismiss allegations it fueled the state's opioid epidemic told lawyers for the state Monday that while they might have shown the pharmacy chain failed to implement an adequate monitoring system, she's still skeptical the company's conduct actually caused the overdose crisis.

  • August 24, 2026

    DOJ Seeks To Beat UC Researchers' Challenge Of Grant Axings

    The U.S. Department of Justice argued on Friday that the Trump administration should prevail over University of California researchers' challenges of the termination of their grants, telling a California federal judge that the First Amendment doesn't apply to competitively awarded grants.

  • August 24, 2026

    Biopharma Co. Brass Sued Over 'Channel Stuffing' Disclosures

    The top brass of pharmaceutical company ADMA Biologics Inc., among other things, failed to disclose certain related-party transactions the company engaged in and a channel-stuffing scheme to create the appearance of revenue, according to a shareholder derivative suit filed Monday.

  • August 24, 2026

    Judge Preserves, But Narrows, IP Verdict Against NuVasive

    A Delaware federal judge on Monday kept in place much of a jury's infringement findings against NuVasive in a doctor's case against it over a group of spinal implant patents but found the jury's other infringement conclusions weren't supported by enough evidence.

  • August 24, 2026

    Tribal Opioid Suits Against Sacklers Slated For $175M Exit

    Dozens of Native American tribes have asked an Ohio federal court to dismiss their lawsuits against members of the Sackler family, which owns bankrupt opioid maker Purdue Pharma, based on a settlement agreement that will pay $175 million to the tribes over 16 years.

  • August 24, 2026

    Merck Loses HHS Suit Over Medicare Drug Price Program

    A D.C. federal judge shot down Merck's challenge to the Inflation Reduction Act's Drug Price Negotiation Program on Monday, ruling that the pharmaceutical giant's voluntary participation in connected Medicare and Medicaid programs meant that its inclusion in the negotiation program doesn't constitute an unconstitutional taking.

  • August 24, 2026

    DOJ Backs Biotech Co. Against Red Cross At 1st Circ.

    The U.S. Department of Justice is continuing to back a biotech company that accuses the American Red Cross of blocking competition for blood platelet testing, telling the First Circuit the nonprofit is not part of the government and is not immune from the antitrust claims.

  • August 24, 2026

    Colo. Judge Certifies Class In Hospital Gender Care Suit

    A Colorado state judge granted class certification in transgender adolescents' lawsuit seeking to have Children's Hospital Colorado resume providing gender-affirming medical care for them and other transgender youth patients.

  • August 24, 2026

    DaVita Defeats Nurse Overtime Collective Bid

    A Colorado federal judge refused to conditionally certify a 41-state collective of DaVita nurses and technicians who say the company denied them overtime by failing to pay for short rest breaks, finding too little evidence of a companywide practice.

  • August 24, 2026

    Fed. Circ. Agrees To Speed Up Args In COVID Vax Patent Case

    The Federal Circuit on Monday agreed to accelerate the schedule in a COVID-19 vaccine patent dispute between Moderna and Arbutus Biopharma Corp. by holding arguments in November.

  • August 24, 2026

    3 Firms Build Biotech Merger With $150M In Private Funding

    Biopharmaceutical company Werewolf Therapeutics and clinical-stage biotechnology firm Ambros Therapeutics have agreed to merge in an all-stock deal built by three law firms, and includes $150 million in private funding.

  • August 24, 2026

    Judge Orders $245M In Guardant Damages In DNA Patent Suit

    A judge has boosted what Guardant Health Inc. owes in a case in which it was found to have infringed two TwinStrand Biosciences Inc. patents covering methods of lowering the error rate in DNA sequencing, bringing the total to $245 million.

  • August 24, 2026

    Rising Star: Paul Weiss' Benjamin Goodchild

    Benjamin Goodchild of Paul Weiss Rifkind Wharton & Garrison LLP developed an innovative deal structure while guiding obesity drug developer Metsera Inc. through a tumultuous bidding war that resulted in its acquisition by Pfizer Inc., earning him a spot among the life sciences law practitioners under age 40 honored by Law360 as Rising Stars.

  • August 24, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week saw a wave of lawsuits involving corporate oversight, take-private deals, financing transactions, bankruptcy fallout, stockholder voting rights and disputes over control.

  • August 21, 2026

    Cytek Hit With $56M Verdict For Infringing Cell-Sorting Patent

    A Delaware federal jury Friday awarded roughly $36 million in damages to biomedical testing manufacturer Beckman Coulter after finding that Cytek Biosciences infringed one of its patents covering a technology that quickly analyzes single cells.

  • August 21, 2026

    Trump Seeks Justices' Review Of DEI Grant Termination Case

    The Trump administration is urging the U.S. Supreme Court to review a Ninth Circuit decision requiring the federal government to reinstate research grants that were terminated due to presidential orders against diversity, equity and inclusion initiatives.

  • August 21, 2026

    Pharma Co. Loses Challenge To $3M Acne Drug Arb. Award

    A New York federal court confirmed an arbitrator's finding that Sun Pharmaceuticals breached an agreement with the owner of an acne drug by seeking regulatory approval to market a version of the drug in Canada, rejecting arguments that the arbitrator wrongly relied on extrinsic evidence.

  • August 21, 2026

    Hogan Lovells Helps Advance Gene Therapy For Rare Disease

    Hogan Lovells Cadwalader partner Blake Wilson found himself scrolling through LinkedIn one day, when a post caught his eye that would spark a multiyear pro bono effort and lead to a breakthrough treatment for a rare and fatal disorder affecting children.

  • August 21, 2026

    Astrid Investor Asks Chancery Court To Order Annual Meeting

    A director and major stockholder of Astrid Pharma Corp. has asked the Delaware Chancery Court to force the company to hold its 2026 annual meeting, saying it has gone years without giving stockholders the chance to elect directors.

  • August 21, 2026

    Bio-Techne Gives FTC More Time On $11.3B Merck Deal

    Life science tool company Bio-Techne has withdrawn and refiled its intent to merge with pharmaceutical giant Merck in an $11.3 billion deal in order to give the Federal Trade Commission more time to scrutinize the deal for competition concerns.

  • August 21, 2026

    Cook Medical Hit With Data Breach Class Suit

    A medical equipment manufacturer failed to protect employees' sensitive data from a cyberattack, potentially exposing their personal information to the dark web, a former employee alleged in a new proposed class action in Indiana federal court.

  • August 20, 2026

    Abbott Inks $670M Deal To End Some Preterm Formula Claims

    Abbott Laboratories announced Thursday that it has agreed to pay about $670 million to partially resolve ongoing litigation alleging its specialty baby formula caused premature babies to suffer a disabling intestinal condition.

  • August 20, 2026

    FTC Slams Amgen's Antitrust Shield Argument At 4th Circ.

    The Federal Trade Commission has urged the Fourth Circuit to reject Amgen's "sweeping" assertion that commercial agreements for acquiring the rights to patent applications are shielded from antitrust scrutiny, saying the company's position in an appeal related to blockbuster autoimmune drug Enbrel is a threat to longstanding understandings of antitrust law.

Expert Analysis

  • Opinion

    PTAB Needs Reform To Protect Inventors From Larger Cos.

    Author Photo

    The Promoting and Respecting Economically Vital American Innovation Leadership Act is necessary because it will impose additional requirements on patent validity challenges and prevent large corporations from taking advantage of the Patent Trial and Appeal Board to overwhelm small inventors with repeated litigation, says Eb Bright at ExploraMed Development.

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

  • What New Animal Welfare Enforcement Push Means For Cos.

    Author Photo

    The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.

  • How To Engage With Gov't's Direct-To-Consumer Drug Policy

    Author Photo

    The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.

  • Series

    Podcasting Makes Me A Better Lawyer

    Author Photo

    Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.